Innovent Biologics, a China-based pharmaceutical company, has collaborated with Shenzhen Chipscreen Biosciences, to assess a combination therapy made up of their respective drugs in colorectal cancer patients, it was reported yesterday.
According to the collaboration, both parties will assess the safety and tolerability of the combination therapy of Innovent's Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death protein one (anti-PD-1) monoclonal antibody and IBI305, a biosimilar product candidate of bevacizumab and a recombinant humanised anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, with Chipscreen Biosciences' Chidamide, a benzamide-based selective inhibitor of class I (subtypes 1, 2, 3) and IIb (subtype 10) histone deacetylases (HDACs), in patients with advanced colorectal cancer.
According to the terms of the contract, both firms will work jointly in China to explore potential applications of this combination on colorectal cancer and to assess its safety and tolerability.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval